A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
'Iodobenzenes' are aromatic organic compounds consisting of a benzene ring substituted with an iodine atom (I), typically represented by the chemical formula C6H5I.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Tumors or cancer of the ADRENAL GLANDS.
An inorganic compound that is used as a source of iodine in thyrotoxic crisis and in the preparation of thyrotoxic patients for thyroidectomy. (From Dorland, 27th ed)
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.
A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.

Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after beta-blocker or angiotensin-converting enzyme inhibitor therapy. (1/545)

Impaired cardiac sympathetic activity can be evaluated by 123I-metaiodobenzylguanidine (MIBG) imaging. METHODS: We studied the significance of MIBG imaging for 24 patients (age 58+/-12 y) with dilated cardiomyopathy (DCM). We compared 12 patients (group A) treated with metoprolol (dose from 30-60 mg/d) with 12 patients treated with angiotensin-converting enzyme (ACE) inhibitors. Patients were studied before treatment, after 5 mo of treatment (only in group A) and after 1 y of treatment. Cardiac MIBG uptake was assessed as the heart-to-mediastinum activity ratio (H/M) and total defect score (TDS) from anterior planar and SPECT MIBG images, which were acquired in 4 h after tracer injection. New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) calculated by echocardiography were also assessed. RESULTS: TDS decreased in both groups (in group A, from 30+/-7 through 23+/-9 to 18+/-10; P < 0.01, in group B, from 30+/-6 to 24+/-8; P < 0.01) and H/M was increased in both groups (in group A, from 1.87+/-0.31 through 2.03+/-0.28 to 2.14+/-0.29; P < 0.01, in group B, from 1.82+/-0.28 to 1.94+/-0.26; P < 0.05). But TDS and H/M were more improved in group A than in group B (P < 0.05). LVEF was significantly increased in only group A (from 38+/-6 through 43+/-8 to 49%+/-9%; P < 0.01). NYHA improved in both groups (in group A, from mean 2.5 through 2.1 to 1.8; P < 0.01, in group B, from mean 2.6 to 2.1; P < 0.05) but was more improved in group A than in group B (P < 0.05). CONCLUSION: Cardiac function, symptom and cardiac sympathetic activity evaluated by MIBG images improved after the beta-blocker therapy more than with the treatment that used ACE inhibitors.  (+info)

Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. (2/545)

Norepinephrine (NE) reuptake function is impaired in heart failure and this may participate in myocyte hyperstimulation by the neurotransmitter. This alteration can be assessed by 123I-metaiodobenzylguanidine (MIBG) scintigraphy. METHODS: To determine whether the impairment of neuronal NE reuptake was reversible after metoprolol therapy, we studied 18 patients (43+/-7 y) with idiopathic dilated cardiomyopathy who were stabilized at least for 3 mo with captopril and diuretics. Patients underwent, before and after 6 mo of therapy with metoprolol, measurements of radionuclide left ventricular ejection fraction (LVEF), maximal oxygen consumption and plasma NE concentration. The cardiac adrenergic innervation function was scintigraphically assessed with MIBG uptake and release measurements on the planar images obtained 20 min and 4 h after tracer injection. To evaluate whether metoprolol had a direct interaction with cardiac MIBG uptake and release, six normal subjects were studied before and after a 1-mo metoprolol intake. RESULTS: In controls, neither cardiac MIBG uptake and release nor circulating NE concentration changed after the 1-mo metoprolol intake. Conversely, after a 6-mo therapy with metoprolol, patients showed increased cardiac MIBG uptake (129%+/-10% versus 138%+/-17%; P = 0.009), unchanged cardiac MIBG release and decreased plasma NE concentration (0.930+/-412 versus 0.721+/-0.370 ng/mL; P = 0.02). In parallel, patients showed improved New York Heart Association class (2.44+/-0.51 versus 2.05+/-0.23; P = 0.004) and increased LVEF (20%+/-8% versus 27%+/-8%; P = 0.0005), whereas maximal oxygen uptake remained unchanged. CONCLUSION: Thus, a parallel improvement of myocardial NE reuptake and of hemodynamics was observed after a 6-mo metoprolol therapy, suggesting that such agents may be beneficial in heart failure by directly protecting the myocardium against excessive NE stimulation.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (3/545)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG). (4/545)

meta-iodobenzylguanidine (MIBG) radiolabelled with iodine-131 is used for diagnosis and treatment of neuroadrenergic neoplasms such as phaeochromocytoma and neuroblastoma. In addition, non-radiolabelled MIBG, administered i.v., is used in several clinical studies. These include palliation of the carcinoid syndrome, in which MIBG proved to be effective in 60% of the patients. Oral MIBG administration might be convenient to maintain palliation and possibly improve the percentage of responders. We have, therefore, investigated the feasibility of oral administration of MIBG in an animal model. Orally administered MIBG demonstrated a bioavailability of 59%, with a maximal tolerated dose of 60 mg kg(-1). The first and only toxicity encountered was a decrease in renal function, measured by a reduced clearance of [51Cr]EDTA and accompanied by histological tubular damage. Repeated MIBG administration of 40 mg kg(-1) for 5 sequential days or of 20 mg kg(-1) for two courses of 5 sequential days with a 2-day interval did not affect renal clearance and was not accompanied by histological abnormalities in kidney, stomach, intestines, liver, heart, lungs, thymus, salivary glands and testes. Because of a sufficient bioavailability in absence of gastrointestinal toxicity, MIBG is considered suitable for further clinical investigation of repeated oral administration in patients.  (+info)

Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. (5/545)

OBJECTIVES: This prospective study was undertaken to correlate early and late metaiodobenzylguanidine (MIBG) cardiac uptake with cardiac hemodynamics and exercise capacity in patients with heart failure and to compare their prognostic values with that of peak oxygen uptake (VO2). BACKGROUND: The cardiac fixation of MIBG reflects presynaptic uptake and is reduced in heart failure. Whether it is related to exercise capacity and has better prognostic value than peak VO2 is unknown. METHODS: Ninety-three patients with heart failure (ejection fraction <45%) were studied with planar MIBG imaging, cardiopulmonary exercise tests and hemodynamics (n = 44). Early (20 min) and late (4 h) MIBG acquisition, as well as their ratio (washout, WO) were determined. Prognostic value was assessed by survival curves (Kaplan-Meier method) and uni- and multivariate Cox analyses. RESULTS: Late cardiac MIBG uptake was reduced (131+/-20%, normal values 192+/-42%) and correlated with ejection fraction (r = 0.49), cardiac index (r = 0.40) and pulmonary wedge pressure (r = -0.35). There was a significant correlation between peak VO2 and MIBG uptake (r = 0.41, p < 0.0001). With a mean follow-up of 10+/-8 months, both late MIBG uptake (p = 0.04) and peak VO2 (p < 0.0001) were predictive of death or heart transplantation, but only peak VO2 emerged by multivariate analysis. Neither early MIBG uptake nor WO yielded significant insights beyond those provided by late MIBG uptake. CONCLUSIONS: Metaiodobenzylguanidine uptake has prognostic value in patients with wide ranges of heart failure, but peak VO2 remains the most powerful prognostic index.  (+info)

Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. (6/545)

Myocardial imaging with 123I-metaiodobenzylguanidine (MIBG) was performed on 35 patients with Parkinson's disease and 24 control subjects to evaluate cardiac sympathetic function in patients with Parkinson's disease, verify this phenomenon and examine whether myocardial MIBG uptake and clearance are correlated with the clinical severity of Parkinson's disease. METHODS: We studied 35 patients with Parkinson's disease and 24 control subjects with other central nervous system diseases. The latter group consisted of 12 subjects with other neurodegenerative disorders (4 with spinocerebellar degeneration, 2 with amyotrophic lateral sclerosis, 3 with progressive supranuclear palsy and 3 with corticobasal degeneration and 12 patients with cerebral infarction (CI), 6 with vascular parkinsonism and 6 without it. Early and delayed images of the anterior view were obtained 15 min and 4 h after injection of 123I-MIBG, respectively. MIBG uptake was quantified by calculating a heart-to-mediastinum count (H/M) ratio. RESULTS: The H/M ratio was markedly reduced in the patients with Parkinson's disease (II to V on the Hoehn and Yahr scale) compared with the control subjects. None of the subjects with neurodegenerative diseases showed a marked decrease in myocardial MIBG uptake nor did any subject with CI. CONCLUSION: Our findings indicate that, in Parkinson's disease, a reduction in myocardial MIBG uptake is a very common, specific phenomenon that can be used to detect cardiac autonomic dysfunction to diagnose Parkinson's disease, particularly in patients without typical signs and symptoms.  (+info)

Myocardial stunning caused by sympathetic nerve injury after an operation on cervical vertebrae. (7/545)

In this case, electrocardiographic inverted T waves appeared after cervical laminaplasty and echocardiogram showed temporary wall motion abnormality. Myocardial metaiodobenzylguanidine (MIBG) uptake was obviously reduced in the same area where the wall motion abnormalities appeared in the echocardiogram, although no abnormalities were detected with myocardial thallium scintigraphy and coronary angiography. The myocardial stunning was caused by injury to the sympathetic nerves from a surgical procedure on the cervical vertebrae.  (+info)

(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. (8/545)

OBJECTIVES: (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson's disease, (2) the usefulness of (123)I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in (123)I-MIBG myocardial scintigraphy, (4) the usefulness of (123)I-MIBG myocardial scintigraphy to differentiate Parkinson's disease from the other neurological diseases mimicking it. METHODS: (123)I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson's disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy. RESULTS: In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson's disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson's disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia. CONCLUSION: (123)I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson's disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson's disease.  (+info)

3-Iodobenzylguanidine (3-IBG) is a radioactive tracer drug that is used in nuclear medicine to help diagnose and evaluate pheochromocytomas and paragangliomas, which are rare tumors of the adrenal glands or nearby nerve tissue. It works by accumulating in the cells of these tumors, allowing them to be detected through imaging techniques such as single-photon emission computed tomography (SPECT) scans.

The drug contains a radioactive isotope of iodine (I-123 or I-131) that emits gamma rays, which can be detected by a gamma camera during the imaging procedure. The 3-IBG molecule also includes a guanidine group, which selectively binds to the norepinephrine transporter (NET) on the surface of the tumor cells, allowing the drug to accumulate within the tumor tissue.

It is important to note that the use of 3-IBG should be under the supervision of a qualified healthcare professional, as it involves exposure to radiation and may have potential side effects.

Iodobenzenes are organic compounds that contain a iodine atom (I) attached to a benzene ring. The general formula for iodobenzenes is C6H5I. They can be considered as aryl halides and can undergo various chemical reactions such as nucleophilic substitution, electrophilic aromatic substitution, and reduction. Iodobenzenes are less reactive than other aryl halides due to the larger size and lower electronegativity of iodine compared to other halogens. They are used in organic synthesis as building blocks or reagents for various chemical transformations.

Iodine radioisotopes are radioactive isotopes of the element iodine, which decays and emits radiation in the form of gamma rays. Some commonly used iodine radioisotopes include I-123, I-125, I-131. These radioisotopes have various medical applications such as in diagnostic imaging, therapy for thyroid disorders, and cancer treatment.

For example, I-131 is commonly used to treat hyperthyroidism and differentiated thyroid cancer due to its ability to destroy thyroid tissue. On the other hand, I-123 is often used in nuclear medicine scans of the thyroid gland because it emits gamma rays that can be detected by a gamma camera, allowing for detailed images of the gland's structure and function.

It is important to note that handling and administering radioisotopes require specialized training and safety precautions due to their radiation-emitting properties.

Pheochromocytoma is a rare type of tumor that develops in the adrenal glands, which are triangular-shaped glands located on top of each kidney. These tumors produce excessive amounts of hormones called catecholamines, including adrenaline and noradrenaline. This can lead to a variety of symptoms such as high blood pressure, sweating, headaches, rapid heartbeat, and anxiety.

Pheochromocytomas are typically slow-growing and can be benign or malignant (cancerous). While the exact cause of these tumors is not always known, some genetic factors have been identified that may increase a person's risk. Treatment usually involves surgical removal of the tumor, along with medications to manage symptoms and control blood pressure before and after surgery.

Adrenal gland neoplasms refer to abnormal growths or tumors in the adrenal glands. These glands are located on top of each kidney and are responsible for producing hormones that regulate various bodily functions such as metabolism, blood pressure, and stress response. Adrenal gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign adrenal tumors are called adenomas and are usually small and asymptomatic. However, some adenomas may produce excessive amounts of hormones, leading to symptoms such as high blood pressure, weight gain, and mood changes.

Malignant adrenal tumors are called adrenocortical carcinomas and are rare but aggressive cancers that can spread to other parts of the body. Symptoms of adrenocortical carcinoma may include abdominal pain, weight loss, and hormonal imbalances.

It is important to diagnose and treat adrenal gland neoplasms early to prevent complications and improve outcomes. Diagnostic tests may include imaging studies such as CT scans or MRIs, as well as hormone level testing and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Potassium iodide is an inorganic, non-radioactive salt of iodine. Medically, it is used as a thyroid blocking agent to prevent the absorption of radioactive iodine in the event of a nuclear accident or radiation exposure. It works by saturating the thyroid gland with stable iodide, which then prevents the uptake of radioactive iodine. This can help reduce the risk of thyroid cancer and other thyroid related issues that may arise from exposure to radioactive materials. Potassium iodide is also used in the treatment of iodine deficiency disorders.

An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.

Nuclear medicine is a branch of medical imaging that uses small amounts of radioactive material, called radiopharmaceuticals, to diagnose and treat various diseases. The radiopharmaceuticals are taken internally, usually through injection or oral administration, and accumulate in specific organs or tissues. A special camera then detects the radiation emitted by these substances, which helps create detailed images of the body's internal structures and functions.

The images produced in nuclear medicine can help doctors identify abnormalities such as tumors, fractures, infection, or inflammation. Additionally, some radiopharmaceuticals can be used to treat certain conditions, like hyperthyroidism or cancer, by delivering targeted doses of radiation directly to the affected area. Overall, nuclear medicine provides valuable information for the diagnosis, treatment planning, and monitoring of many medical conditions.

Iodine is an essential trace element that is necessary for the production of thyroid hormones in the body. These hormones play crucial roles in various bodily functions, including growth and development, metabolism, and brain development during pregnancy and infancy. Iodine can be found in various foods such as seaweed, dairy products, and iodized salt. In a medical context, iodine is also used as an antiseptic to disinfect surfaces, wounds, and skin infections due to its ability to kill bacteria, viruses, and fungi.

Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine ( ... ISBN 978-3-319-68872-5. S2CID 52922868. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. (September 2019). " ... doi:10.1007/s00259-008-0715-3. PMID 18274745. S2CID 6884201. Van Vickle SS, Thompson RC (June 2015). "123I-MIBG Imaging: ...
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine ( ... 4 KI + 2 CO 2 + O 2 ⟶ 2 K 2 CO 3 + 2 I 2 {\displaystyle {\ce {4 KI + 2 CO2 + O2 -> 2 K2CO3 + 2 I2}}} Since the iodide ion is a ... 3 December 2015. "Assessment of the Use of Potassium Iodide (KI) As a Public Protective Action During Severe Reactor Accidents ... The dose typically begins with a loading dose, then 1⁄3 mL SSKI (5 drops or 250 mg iodine as iodide), three times per day. ...
5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole MeSH D02.640.600.290 - fanft MeSH D02.640.600.308 - furagin MeSH D02.640. ... 3-oxo-1,5-pentanediyl)bis(n,n-dimethyl-n-2-propenyl-), dibromide MeSH D02.092.146.325 - p-dimethylaminoazobenzene MeSH D02.092. ... vitamin k 3 MeSH D02.455.849.291.850 - taxoids MeSH D02.455.849.291.850.777 - paclitaxel MeSH D02.455.849.365 - dolichol MeSH ... 3-diketogulonic acid MeSH D02.241.081.844.300 - glucaric acid MeSH D02.241.081.844.322 - gluconates MeSH D02.241.081.844. ...
Another way to detect neuroblastoma is the meta-iodobenzylguanidine scan, which is taken up by 90 to 95% of all neuroblastomas ... ISBN 978-3-540-26616-7. Beckwith JB, Perrin EV (December 1963). "In Situ Neuroblastomas: A Contribution to the Natural History ... 115 (3-4): 273-282. doi:10.1159/000095924. PMID 17124410. S2CID 14012430. Carén H, Erichsen J, Olsson L, Enerbäck C, Sjöberg RM ... Stage 3: Tumor infiltrating across midline with or without regional lymph node involvement; or unilateral tumor with ...
"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy" (PDF). 17 June 2009. Archived from the ... 29 (1-3): 185-205. ISSN 0393-9375. "Where do we get iodine from?". Iodine Global Network. Archived from the original on 13 ... 851-3 Greenwood and Earnshaw, pp. 853-9 Greenwood and Earnshaw, pp. 863-4 Greenwood and Earnshaw, pp. 872-5 Greenwood and ... ISBN 978-3-540-93516-2. Greenwood and Earnshaw, pp. 804-9 Windholz, Martha; Budavari, Susan; Stroumtsos, Lorraine Y.; Fertig, ...
... meta-iodobenzylguanidine (MIBG) imaging for neuroendocrine tumors, heat-damaged red blood cell imaging for identifying ectopic ... 1996 Jul;26(3):191-193. PMID 8829280. PET center of excellence ABNM brochure Archived 2007-07-01 at the Wayback Machine nuclear ...
Iodine-123-meta-iodobenzylguanidine myocardial scintigraphy can help locate denervation of the muscles of the heart which can ... 9 (Suppl 3): 23-30. doi:10.1046/j.1468-1331.9.s3.3.x. PMID 12464118. Gibb WR, Lees AJ (June 1988). "The relevance of the Lewy ... 3 (1): 17013. doi:10.1038/nrdp.2017.13. PMID 28332488. S2CID 11605091. Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB ( ... Males are affected at a ratio of around 3:2 compared with females. When it is seen in people before the age of 50, it is called ...
Explore the 8 possible supplements interactions for 3-Iodobenzylguanidine and the research papers that mention these ...
Experimental studies have shown that cytokine production by the heart may be regulated by sympathetic nervous system stimulation of cardiac beta-adrenergic receptors. Proinflammatory cytokine levels are increased in heart failure, whereas cardiac fixation of 123-I-metaiodobenzylguanidine (MIBG) has …
Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (May 2008). "EANM procedure guidelines for 131I-meta-iodobenzylguanidine ( ... ISBN 978-3-319-68872-5. S2CID 52922868. Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. (September 2019). " ... doi:10.1007/s00259-008-0715-3. PMID 18274745. S2CID 6884201. Van Vickle SS, Thompson RC (June 2015). "123I-MIBG Imaging: ...
Assessment of cardiac adrenergic supply in mitral valve prolapse using m-[123I]iodobenzylguanidine scintigraphy. Int J Cardiol ... Reports vary, but 3-5% of pediatric patients likely have clinically significant mitral valve prolapse. However, a report from ... Atrioventricular valve morphology and dynamics in congenital heart disease as imaged with real-time 3-dimensional matrix-array ... Accuracy of real-time 3-dimensional echocardiography in the assessment of mitral prolapse. Is transesophageal echocardiography ...
I-123 meta-iodobenzylguanidine, I-123-MIBG). If uncontaminated I 123, discontinue breastfeeding for 12, 24 or 48 hours ... I-123 as sodium iodide (123 I-NaI). If uncontaminated with I 125: doses up to 20 MBq (0.5 mCi) waiting time= 3 to 6 hours. If ... 3 weeks (Sachs 2013, ICRP 2008). For more safety, you can request to measure the amount of radioactivity of the milk in the ... 3 weeks (Sachs 2013, ICRP 2008). I-123 as ioflupane: Stop breastfeeding from 1 day (Society of Nuclear Medicine, Djang 2012) to ...
A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. ... Adrenal medullary imaging; Meta-iodobenzylguanidine scintiscan; Pheochromocytoma - MIBG; Neuroblastoma - MIBG; Carcinoid MIBG ... You may need to return for repeated scans for 1 to 3 days. Each scan takes 1 to 2 hours. ...
... meta-iodobenzylguanidine, [(1)F]fluorodopamine, and [(3)H]norepinephrine in mouse pheochromocytoma cells and tumors after ... 3 Feng F, Zhu Y, Wang X, Wu Y, Zhou W, Jin X, Zhang R, Sun F, Kasoma Z, Shen Z. Predictive factors for malignant ... 3 Department of Endocrine Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA ... 3 Department of Endocrine Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA ...
A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. ... Adrenal medullary imaging; Meta-iodobenzylguanidine scintiscan; Pheochromocytoma - MIBG; Neuroblastoma - MIBG; Carcinoid MIBG ... You may need to return for repeated scans for 1 to 3 days. Each scan takes 1 to 2 hours. ...
... evaluating induction therapy followed by meta-iodobenzylguanidine labeled with iodine-131 and chemotherapy in treating patients ... Presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL. Abstract 10005. ... with high-risk neuroblastoma treated in 3 upfront COG trials from 2007 to 2016: ANBL0532 (NCT00567567) evaluating 2 high-dose ...
m Iodobenzylguanidine m-Iodobenzylguanidine meta Iodobenzylguanidine meta-Iodobenzylguanidine Iobenguane (131I) - Narrower ... m Iodobenzylguanidine. m-Iodobenzylguanidine. meta Iodobenzylguanidine. meta-Iodobenzylguanidine. Tree number(s):. D02.078. ... 3-Iodobenzylguanidine - Preferred Concept UI. M0029373. Scope note. A guanidine analog with specific affinity for tissues of ... 125I Labeled 3-Iodobenzylguanidine 3 Iodobenzylguanidine, 125I Labeled (3-Iodo-(131I)benzyl)guanidine - Narrower Concept UI. ...
3, p. 302-308 7 p.. Research output: Contribution to journal › Article › peer-review ...
A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: evaluation for (131)I ... 3, p. 399-405 7 p.. Research output: Contribution to journal › Article › peer-review ...
Dive into the research topics where Marie Boyd is active. These topic labels come from the works of this person. Together they form a unique fingerprint ...
3, p. 299-308 10 p.. Research output: Contribution to journal › Article › peer-review ...
Neuroblastoma, MIBG, 131I-MIBG, Resistant, Relapsed, Treatment, University of California, San Francisco, Pediatric, Oncology, 3 ... Iodobenzylguanidine, Metaiodobenzylguanidine (MIBG). Eligibility. You can join if… Open to people ages 1 year and up ... Patients with active infections that meet grade 3-4 toxicity criteria.. *Patients with pheochromocytoma or paraganglioma who ...
123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis ... Although pheochromocytomas have classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple ...
... iodobenzyl)guanidine. [11C]b-CIT. methyl 3-(4-iodocyclohexyl)-8-[11C]methyl-8-azabicyclo[3.2.1]octane-2-carboxylate. Articles ... 2E,2E)-3,3-[(2,2-dimethylpropane-1,3-diyl)diimino]dibutan-2-one dioximato-oxo[99mTc]technetium(V) [99mTc]MIBI. Hexa(1- ... G Ital Dermatol Venereol 2018;153 (3 Suppl 2), 20-5.. Books and monographs. For occasional publications, the names of authors, ... No more than 1000 words (3 typed, double-spaced pages) and up to 15 references will be accepted.. Original articles. These ...
A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and ...
Iobenguane I 131 is described as I 131 meta-iodobenzylguanidine. The molecular weight is 279.1 Daltons and the structural ... Table 3: Recommended Dose or Dose Reduction for Second Therapeutic Dose of AZEDRA for Myelosuppression Patient Population. If ... 3. Dosage Forms and Strengths. Injection: 555 MBq/mL (15 mCi/mL) as a clear, colorless to pale yellow solution in a single-dose ... icon (Figure 3) or the icon (Figure 4). Note: the running icon will disappear when the monitor is stopped. ...
Iodine-123 meta-iodo-benzylguanidine myocardial imaging in asymptomatic patients, with chronic kidney disease.[AUT.] B[EATA] E ... 3 nr 4 s. 141-153, bibliogr. poz. 50, sum.. *Miażdżyca aorty u osób z chorobą niedokrwienną serca oceniana przy zastosowaniu ... Munich, 30 August - 3 September 2008. Abstr [b. pag.] P1278.. *Influence of head-up tilt test provocation on autonomic nervous ... Munich, 30 August - 3 September 2008. Abstr [b. pag.] P3634.. *Type 1 diabetes mellitus and silent myocardial ischemia.[AUT.] T ...
Noradrenaline and 123I-meta-iodobenzylguanidine Kinetics in the Sympathetic Nervous System -- 14. Technical Considerations for ... 1 Basics of Ultrasound Physics -- 2 Views and Structures -- 3 Chamber Dimensions -- 4 Valvular Quantification -- 5 Valvular ... SECTION 1. Introduction -- SECTION 2. Non-invasive cardiac imaging modalities -- SECTION 3. Invasive cardiac imaging modalities ... 3. Muscle Sympathetic Nerve Activity and Cardiovascular Diseases -- 4. Skin sympathetic nerve activity and thermoregulatory ...
Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA ... Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA ... 123)I mIBG (meta-iodobenzylguanidine) and (111)In pentetreotide scintigraphy imaging modalities are useful in demonstrating ...
Myocardial scintigraphy with iodine 123-meta-iodobenzylguanidine (MIBG; in dementia with Lewy bodies, cardiac uptake of MIBG is ... Before death, patients tend to follow 1 of 3... read more may be more appropriate than highly aggressive interventions or ... Single-photon emission CT (SPECT) of the brain with 123I-FP-CIT (N-3-fluoropropyl-2-beta-carbomethoxy-3beta-[4-iodophenyl]- ...
131I-meta-iodobenzylguanidine scintigraphy in patients with a suspected pheochromocytoma. A comparison with CT and biohumoral ... We investigated the usefulness of molecular imaging with meta-iodobenzylguanidine (MIBG) for evaluating the effects of ... Endocrine (ISSN: 1355-008x), 2016 Jun; 52(3): 488-494.. Impact Factor: 3.131. View Export to BibTeX Export to EndNote. Longo DL ... Curr Cardiovasc Imaging Rep (ISSN: 1941-9066), 2014 Jan; 7(3): 1-7.. Impact Factor: 0. View Export to BibTeX Export to EndNote ...
This may help explain recent clinical imaging studies using meta-iodobenzylguanidine (MIBG) and 11C-meta-hydroxyephedrine ... This may help explain recent clinical imaging studies using meta-iodobenzylguanidine (MIBG) and 11C-meta-hydroxyephedrine ... 2010). Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ... and this may be beyond the relatively low-resolution of meta-iodobenzylguanidine and 11C-meta-hydroxyephedrine PET imaging. ...
BACKGROUND: I-123 meta-iodobenzylguanidine (MIBG) imaging has long been employed to noninvasively assess the integrity of human ... Using ROI analysis, the effective half-lives were 13 ± 11 h (range, 5-75 h) for CSF in the spinal column, 8 ± 3 h (range, 3-17 ... Grade 3/4 thrombocytopenia was the most common hematologic toxicity. Recommended phase 2 dose was 1850 MBq/injection. The ... Patients could receive a second cycle in the absence of grade 3/4 non-hematologic toxicity or progressive disease. RESULTS: ...
cardiac sympathetic innervation using iodine-123 meta-iodobenzylguanidine (MIBG). *brain pathology (postmortem) ...
Correction of iodine-123-labeled meta-iodobenzylguanidine uptake with multi-window methods for standardization of the heart-to- ... ESTIMATION OF Hp(3) TO THE EYE LENS OF INTERVENTIONAL RADIOLOGISTS-RELATION BETWEEN THE EYE LENS DOSE AND RADIOLOGISTS HEIGHT ... Comparison between 3-D and z-axis automatic tube current modulation technique in multidetector-row CT Kosuke Matsubara, Kichiro ... Introduction of size-specific dose estimates (SSDE) Kosuke Matsubara Japanese Journal of Computed Tomography Technoology 6 1 3- ...
  • I-123 as iobenguane (I-123 meta-iodobenzylguanidine, I-123-MIBG). (e-lactancia.org)
  • A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. (medlineplus.gov)
  • La MIBG es un agente neurobloqueante con fuerte afinidad y retención en la médula suprarrenal y también inhibe la ADP-ribosiltransferasa. (bvsalud.org)
  • We investigated the usefulness of molecular imaging with meta-iodobenzylguanidine (MIBG) for evaluating the effects of chemotherapy in patients with malignant pheochromocytoma. (cnr.it)
  • This may help explain recent clinical imaging studies using meta-iodobenzylguanidine (MIBG) and 11C-meta-hydroxyephedrine positron emission tomography (PET) which demonstrate that border zone denervation is strongly associated with a high risk of future arrhythmia. (frontiersin.org)
  • Our data therefore strengthen the rationale for using cardiac nuclear imaging with a noradrenergic nuclear imaging ligand, meta-iodobenzylguanidine (MIBG) to separate DLB from AD with DLB, an important concept as most cases of AD/DLB are not recognized as such during life. (mdsabstracts.org)
  • We determined bystander responses generated by the uptake of radioiodinated iododeoxyuridine ([*I]IUdR) and radiohaloanalogues of meta-iodobenzylguanidine ([*I]MIBG) by noradrenaline transporter (NAT) gene-transfected tumour cells. (strath.ac.uk)
  • Radioiodine-labeled meta -iodobenzylguanidine (mIBG) is used as a diagnostic agent ( 123 I-mIBG) and a targeted radiotherapy ( 131 I-mIBG) for neuroendocrine cancers. (aspetjournals.org)
  • SIGNIFICANCE STATEMENT Radiolabeled meta -iodobenzylguanidine (mIBG) has been used as a diagnostic tool and as radiotherapy for neuroendocrine cancers and other diseases. (aspetjournals.org)
  • What is a MIBG scan (meta-iodobenzylguanidine scan) for childhood cancer? (kidshealth.org.nz)
  • This has been exemplified with an effective synthesis of radiolabelled meta-[125I]iodobenzylguanidine, a radiopharmaceutical used for the imaging and therapy of human norepinephrine transporter-expressing tumours. (gla.ac.uk)
  • Although pheochromocytoma has classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN 2), and neurofibromatosis type 1 (NF1)-there are now 10 genes that have been identified as sites of mutations leading to pheochromocytoma. (medscape.com)
  • The most commonly used PET tracer (radiopharmaceutical) to investigate brain dopaminergic function in PD is 3, 4-dihydroxy-6-[ 18 F] fluoro-L-phenyl alanine ( 18 F-FDOPA). (e-jmd.org)
  • Acquire additional images between Days 2-5 following patient voiding (Scan 3). (guidelinecentral.com)
  • online] 2022 vol. 132 nr 10 s. 1-3, bibliogr, [przeglądany 2 września 2022]. (topmedical.pl)
  • Olaparib tablets can be taken with or without food, with the exception of Day 8 (a PK sampling day) when patients aged ≥3 years old receiving tablets should take olaparib at least 1 hour after food and should refrain from eating for up to 2 hours afterwards. (mycancergenome.org)
  • You may need to return for repeated scans for 1 to 3 days. (medlineplus.gov)
  • For each individual patient, calculate the radiation dose estimates to normal organs and tissues per unit activity [D (organ)] of administered dose using data extracted from these 3 images. (guidelinecentral.com)
  • If uncontaminated with I 125: doses up to 20 MBq (0.5 mCi) waiting time= 3 to 6 hours. (e-lactancia.org)
  • 3-5 Thisobser- vationcombinedwiththeirubiquitousdistributioninneuroendo- crine,endocrineandnervoustissuesmakesCgsusefulmarkersof secretion of normal and tumoral neuroendocrine cells. (123dok.net)
  • 8. Meta-iodobenzylguanidine in children. (nih.gov)
  • Hormonal studies and iodine-123 meta-iodobenzylguanidine scintigraphy revealed no neuroendocrine tumor such as a pheochromocytoma. (medscape.com)
  • A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. (medlineplus.gov)
  • Radioiodinated meta-iodobenzylguanidine (MIBG), an analogue of norepinephrine, has been used in management of neuroendocrine tumors. (uni-luebeck.de)
  • Cardiac uptake of meta-iodobenzylguanidine (MIBG) was reduced (H/M ratio: 1.14). (neurology-jp.org)
  • Clinical potential of arylgermanes as radio-iodination precursors is demonstrated through the labelling of [125 I]IMTO (iodometomidate) and [125 I]MIBG (meta-iodobenzylguanidine) thus offering an alternative to radio-iododestannylation processes using non-toxic precursors. (bvsalud.org)
  • Novel targeting agents against neuroblastoma based on the meta -iodobenzylguanidine (MIBG) moiety were synthesized and biologically evaluated for nanocarrier vectorization. (rsc.org)
  • 17. Applications of [131I]m-iodobenzylguanidine ([131I]MIBG). (nih.gov)
  • International agencies state that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 131 MIBG. (nih.gov)
  • 1 , 3 - 5 ] Patients receiving iobenguane I 131usually receive potassium iodide prior to the diagnostic examination to block their thyroid gland's uptake of the I-131 that is released from the I 131 MIBG. (nih.gov)
  • 123 I]MIBG (~74 MBq/μmol) in 3 healthy volunteers by serial imaging and blood sampling. (uni-luebeck.de)
  • 123I]MIBG (~74 MBq/μmol) in 3 healthy volunteers by serial imaging and blood sampling. (uni-luebeck.de)
  • 3. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. (nih.gov)
  • 3-Iodobenzylguanidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
  • Of these patients, 3 patients had metastatic HNPGL. (kl.ac.at)
  • Approximately 3 minutes after suspending the operation, blood pressure returned to baseline levels. (medscape.com)
  • A second cohort was injected with LV-CNTF and a LV encoding suppressor of cytokine signaling 3 (SOCS3), to inhibit the JAK-STAT3 pathway specifically in astrocytes. (bvsalud.org)
  • Finally, MAC was found to trigger apoptotic death pathway (based on expression levels of cleaved-caspase 3, Bax/Bcl-2 balance, p53 and p21). (biomedcentral.com)
  • Although pheochromocytomas have classically been associated with 3 syndromes-von Hippel-Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN 2), and neurofibromatosis type 1 (NF1)-there are now 10 genes that have been identified as sites of mutations leading to these tumors. (medscape.com)
  • You may need to return for repeated scans for 1 to 3 days. (medlineplus.gov)
  • METHODS: A total of 3 men and 7 women (age range 22 to 73 years) with anatomical and/or histologically proven HNPGL were included in this study. (kl.ac.at)
  • This graph shows the total number of publications written about "3-Iodobenzylguanidine" by people in this website by year, and whether "3-Iodobenzylguanidine" was a major or minor topic of these publications. (jefferson.edu)
  • We invite you to complete a survey that will take no more than 3 minutes. (bvsalud.org)